<?xml version="1.0" encoding="UTF-8"?>
<p>The goal of this session is to consider potential obstacles for effective adoption of a repurposed drug to widespread treatment of COVID-19. Both patent protection and scalability of manufacturing processes are key aspects to consider while choosing the best therapeutic option to adopt when dealing with a pandemic.</p>
